Rita M. O’Connor Appointed Chief Financial Officer of PLx Pharma
May 02 2017 - 7:00AM
PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a
late-stage specialty pharmaceutical company focused on
commercializing two patent-protected products, Aspertec™ 325 mg and
Aspertec™ 81 mg (referred to together as “Aspertec”™), announced
today the appointment of Rita M. O’Connor as Chief Financial
Officer (CFO), effective July 1, 2017. Ms. O’Connor succeeds David
Jorden, who has served as the Company’s Acting CFO since June 2015
and previously served as a PLx board member since 2005. Mr. Jorden
will transition at the end of July.
Ms. O’Connor, the former CFO of Mucinex® innovator, Adams
Respiratory Therapeutics, brings an extensive background in
finance, strategic partnering, merger and acquisitions and equity
fundraising in both public and private offerings to PLx, which
recently completed its merger with Dipexium Pharmaceuticals, Inc
(“Dipexium”).
“David has been a valued partner, and we are grateful for his
contributions as Acting CFO and through PLx’s recently-closed
merger with Dipexium. Our transition to a full-time CFO is part of
a natural and planned process that recognizes PLx’s status as a
newly public company. We wish him well in his future endeavors,”
stated Natasha Giordano, President and Chief Executive Officer of
PLx.
“We are pleased to welcome Rita to PLx at this important
juncture in our development as we transition into a
commercial-stage pharmaceutical company. Her considerable financial
acumen and wide-ranging, senior management experience will be
important assets as we seek to commercialize Aspertec, and
essential to our continued success,” added Ms. Giordano.
Ms. O’Connor joins PLx from the Kent Place School, an all-girls
college preparatory school, where she has served as CFO since 2013.
She was previously the CFO and Chief Information Officer at
Xanodyne Pharmaceuticals, an integrated specialty pharmaceutical
company focused on women’s health and pain management, prior to
which she was Chief Financial Officer and Treasurer of Adams
Respiratory Therapeutics, a specialty pharmaceutical company
focused on OTC and prescription products for the treatment of
respiratory disorders.
Earlier in her career she held positions of increasing
responsibility during an eight-year tenure at Schering-Plough
Corporation. She began her career at Deloitte and Touche.
Ms. O'Connor is a licensed certified public accountant and
earned her Bachelor of Science in Accounting from Rutgers
University.
About AspertecAspertec is an
FDA approved aspirin product being developed to provide high-risk
cardiovascular and stroke patients with more reliable and
predictable antiplatelet efficacy as compared to enteric coated
aspirin, while also reducing the adverse gastric events common in
an acute setting. PLx is focused on completing manufacturing
scale-up and label finalization for Aspertec 325 mg aspirin dosage
form and preparing an sNDA for Aspertec 81 mg maintenance dose
form.
About PLx Pharma Inc. PLx Pharma Inc. is
a late-stage specialty pharmaceutical company focused on developing
its clinically validated and patent-protected PLxGuard™ delivery
system to provide safe and effective aspirin products. The PLxGuard
delivery system works by targeting delivery of active
pharmaceutical ingredients (API) to various portions of the
gastrointestinal (GI) tract. PLx believes this has the potential to
improve the absorption of many drugs currently on the market or in
development, and to reduce acute GI side effects—including
erosions, ulcers and bleeding—associated with aspirin and
ibuprofen, and potentially other drugs.
To learn more about PLx Pharma Inc. and its pipeline, please
visit www.plxpharma.com.
Forward Looking StatementsAny
statements made in this press release relating to future financial
or business performance, conditions, plans, prospects, trends, or
strategies and other financial and business matters, including
without limitation, the prospects for commercializing or selling
any products or drug candidates, are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. In addition, when or if used in this press release, the
words “may,” “could,” “should,” “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “plan,” “predict” and similar
expressions and their variants, as they relate to PLx may identify
forward-looking statements. PLx cautions that these forward-looking
statements are subject to numerous assumptions, risks, and
uncertainties, which change over time. Important factors that may
cause actual results to differ materially from the results
discussed in the forward-looking statements or historical
experience include risks and uncertainties, including the failure
by PLx to secure and maintain relationships with collaborators;
risks relating to clinical trials; risks related to any litigation
or post-closing disputes arising out of matters related to PLx’s
merger with Dipexium; risks relating to the commercialization, if
any, of PLx’s proposed product candidates (such as marketing,
regulatory, product liability, supply, competition, and other
risks); dependence on the efforts of third parties; dependence on
intellectual property and risks that PLx may lack the financial
resources and access to capital to fund proposed operations.
Further information on the factors and risks that could affect
PLx’s business, financial conditions and results of operations are
contained in PLx’s filings with the U.S. Securities and
Exchange Commission (SEC), which are available
at www.sec.gov. Other risks and uncertainties are more fully
described in Dipexium’s Registration Statement on Form S-4 filed
with the SEC, and in other filings that PLx will make going
forward. The forward-looking statements represent PLx’s estimate as
of the date hereof only, and PLx specifically disclaims any duty or
obligation to update forward-looking statements.
Contact
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Media:
Ann Smith, Coyne Public Relations
T: 973-588-2385
E: asmith@coynepr.com
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Apr 2023 to Apr 2024